Savara and the PAP Foundation
Form Global Partnership Which Will Support and Unite the Community
of Individuals Afflicted with Pulmonary Alveolar Proteinosis
(PAP)
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, is
pleased to announce a global partnership with the PAP Foundation,
Inc., a non-profit patient advocacy organization dedicated to
improving the lives of those affected by PAP, where Savara will
serve as the inaugural sponsor of the foundation. In this capacity,
Savara will be supporting the PAP Foundation’s efforts to unite,
educate, organize and build the global PAP patient and physician
community, including helping to further expand the PAP patient
registry, as well as offering grant assistance to support
educational awareness efforts, which include the 1st Annual
National PAP Education Day, to be held concurrently with the 2018
Rare Lung Diseases Conference on Saturday, September 8th, 2018.
“The PAP Foundation is grateful for Savara’s
generous support and commitment, not only in helping our foundation
provide education and awareness of PAP to the global patient and
physician communities, but also as the only biotech company
aggressively seeking effective FDA approved therapies for those
afflicted by PAP,” said Christopher Hameetman, President of the PAP
Foundation. “The PAP-patient community is further grateful to
Savara for expediting its U.S. development strategy for Molgradex
(inhaled GM-CSF), which we believe could be an effective treatment
for autoimmune-PAP patients.”
“We at Savara are proud to be a part of the Rare
Disease community and are delighted to be joining the PAP
Foundation on this collaborative, educational effort and the
opportunity to positively impact the global PAP community,” said
Rob Neville, CEO of Savara. “We believe there is a tremendous
opportunity for meaningful impact and this partnership is a
continuation of our proud commitment to support the patient
communities we aim to serve and the organizations that provide
patients, families and caregivers the critical support they
need.”
The Savara / PAP Foundation 1st Annual National
PAP Education Day will be held concurrently with the 2018 Rare Lung
Diseases Conference (RLDC) at the Cincinnati Marriott at
Rivercenter located at 10 W Rivercenter Blvd., Covington, KY 41011
on Saturday, September 8, 2018 from 1:00 PM – 9:00 PM. Everyone in
the PAP community is welcome and attendance is complimentary to any
pulmonary clinicians and registered PAP patients, and their
relatives and support persons (RLDC Tickets / Credentials are not
required for this special event).
For more details, or to register to attend the 1st Annual
National PAP Education Day, please contact Brenna Carey, MS, PhD,
PAP, Foundation Coordinator, either by phone: 513.636.8916, or via
email: brennac@papfoundation.org.
About the PAP FoundationThe PAP
Foundation is a non-profit patient advocacy organization dedicated
to research and education on effective therapies for Pulmonary
Alveolar Proteinosis (PAP), and to improving the lives of those
affected by PAP. PAP is a life-threatening lung disorder that
affects men, women, and children. Through advocacy and
collaboration with a focus on uniting the PAP patient community,
the PAP Foundation promotes research and provides information and
support for PAP patients, healthcare professionals, and the public.
More information can be found on our website at
www.papfoundation.org, and also on social media including Facebook
and Twitter.
About Savara Savara is an
orphan lung disease company. Savara's pipeline comprises Molgradex,
an inhaled granulocyte-macrophage colony-stimulating factor, or
GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar
proteinosis, or aPAP, in Phase 2a development for nontuberculous
mycobacteria, or NTM, lung infection, and in preparation for Phase
2a development in cystic fibrosis, or CF, affected individuals with
chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled
vancomycin for treatment of persistent methicillin resistant
staphylococcus aureus, or MRSA, lung infection in CF. Savara's
strategy involves expanding its pipeline of potentially
best-in-class products through indication expansion, strategic
development partnerships and product acquisitions, with the goal of
becoming a leading company in its field. The most recent
acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready,
proprietary combination antibiotic, which has demonstrated potent
and broad-spectrum antibacterial activity against highly drug
resistant pathogens. Savara's management team has significant
experience in orphan drug development and pulmonary medicine,
identifying unmet needs, developing and acquiring new product
candidates, and effectively advancing them to approvals and
commercialization. More information can be found at
www.savarapharma.com. (Twitter: @SavaraPharma)
Forward-Looking Statements
Savara cautions you that statements in this press release that are
not a description of historical fact are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words referencing future events or circumstances such as "expect,"
"intend," "plan," "anticipate," "believe," and "will," among
others. Such statements include, but are not limited to, statements
regarding Savara’s support of the PAP Foundation’s efforts to
unite, educate, organize and build the global PAP patient and
physician community, including helping to further expand the PAP
patient registry, Savara’s offering of grant assistance to support
educational awareness efforts, including its 1st Annual National
PAP Education Day, Savara being the only biotech company
aggressively seeking effective FDA approved therapies for those
afflicted by PAP, Savara expediting its U.S. development strategy
for Molgradex, the belief that Molgradex could be an effective
treatment for autoimmune-PAP patients, the belief that there is a
tremendous opportunity for meaningful impact, that the partnership
with the PAP Foundation is a continuation of our proud commitment
to support the patient communities we aim to serve and the
organizations that provide patients, families and caregivers the
critical support they need, and our strategy and goals. Savara may
not actually achieve any of the matters referred to in such
forward-looking statements, and you should not place undue reliance
on these forward-looking statements. Because such statements are
subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. These forward-looking statements are based upon
Savara's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with the outcome of our ongoing clinical
trials for our product candidates (including Molgradex), the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient resources for Savara's operations and to
conduct or continue planned clinical development programs
(including our IMPAPLA and IMPALA-X studies of Molgradex), the
ability to obtain the necessary patient enrollment for our product
candidates in a timely manner (including our IMPAPLA and IMPALA-X
studies of Molgradex), the ability to successfully identify
exploratory product pipeline candidates, the ability to
successfully develop our product candidates, the risks associated
with the process of developing, obtaining regulatory approval for
and commercializing drug candidates such as Molgradex, AeroVanc and
amikacin/fosfomycin that are safe and effective for use as human
therapeutics, and the timing and ability of Savara to raise
additional equity capital if needed to fund continued operations.
All forward-looking statements are expressly qualified in their
entirety by these cautionary statements. For a detailed description
of our risks and uncertainties, you are encouraged to review our
documents filed with the SEC including our recent filings on Form
8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue
reliance on forward-looking statements, which speak only as of the
date on which they were made. Savara undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as may be required by law.
Contacts: PAP Foundation: Brenna Carey, MS, PhD
(brennac@papfoundation.org) PAP Foundation Coordinator (513)
636-8916 Savara: Ioana C. Hone (ir@savarapharma.com) (512)
961-1891
For IR: Solebury Trout Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
For Media: Neon InteractivePatrick Wallace
(patrick@neoninteractive.com) (619) 200-7856
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Apr 2023 to Apr 2024